Growth funding The company recently secured $12M in growth funding from Trinity Capital in 2023, signaling readiness for scale. This presents an opportunity to offer expansion-focused solutions, strategic partnerships, and services that support rapid deployment and broader market reach.

Clinical leadership With a history of FDA-cleared SoftVue Breast Tomographic Ultrasound and recent CMO transition, there is a need to bolster clinical development, medical affairs, and payer strategies. Sales discussions can emphasize regulatory support, clinical evidence generation, and reimbursement positioning.

Product expansion SoftVue’s unique ring transducer and TriAD technology position Delphinus as a differentiated imaging platform. There is potential to upsell integration services, software updates, training programs, and data analytics capabilities to maximize diagnostic value for imaging centers.

Market momentum Awards and industry recognition such as the Technology Breakthrough award in 2024 and Minnies finalist status in 2022 indicate rising adoption and credibility. This supports outbound campaigns targeting radiology groups, cancer centers, and comprehensive imaging networks.

Operational scale With a lean team (11-50 employees) and substantial funding, there is opportunity to offer scalable services (implementation, maintenance, and remote monitoring) and partner ecosystems to accelerate deployment at multiple sites while maintaining high service quality.